S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)

• C. Carlo-Stella,
• S. Ansell,
• P. L Zinzani,
• J. Radford,
• K. Maddocks,
• A. Pinto,
• G. P. Collins,
• V. Bachanova,
• N. Bartlett,
• I. Bence-Bruckler,
• M. Hamadani,
• J. Kline,
• J. Mayer,
• K. J. Savage,
• R. Advani,
• P. Caimi,
• R.-O. Casasnovas,
• T. Feldman,
• B. Hess,
• M. Bastos-Oreiro,
• S. Iyengar,
• S. Eisen,
• Y. Negievich,
• L. Wang,
• J. Wuerthner,
• A. F. Herrera

Affiliations

C. Carlo-Stella

1 Department of Oncology and Hematology, Humanitas Clinical and Research Center - IRCCS and Humanitas University, Rozzano, Milano, Italy

S. Ansell

2 Division of Hematology, Mayo Clinic, Division of Hematology, Minnesota, United States of America

P. L Zinzani

3 Hematology, Institute of Hematology Seràgnoli University of Bologna, Bologna, Italy

J. Radford

4 NIHR Clinical Research Facility, the Christie NHS Foundation Trust and University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom

K. Maddocks

5 Division of Hematology, Ohio State University Medical Center, Columbus, United States of America

A. Pinto

6 Fondazione G. Pascale, IRCCS, Istituto Nazionale Tumori, Naples, Italy

G. P. Collins

7 Oxford Cancer and Haematology Centre, NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom

V. Bachanova

8 Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis

N. Bartlett

9 Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, United States of America

I. Bence-Bruckler

10 Ottawa-Hospital General Campus, The Ottawa Hospital-General Campus, Ottawa, Canada

M. Hamadani

11 Medical College of Wisconsin, BMT & Cellular Therapy Program, Department of Medicine, Milwaukee

J. Kline

12 Department of Medicine, The University of Chicago, Chicago, United States of America

J. Mayer

13 Internal Medicine, University Hospital and Masaryk University, Brno, Czechia

K. J. Savage

14 Department of Medical Oncology, BC Cancer and University of British Columbia, Vancouver, Canada

R. Advani

15 Division of Oncology, Department of Medicine, Stanford University, Stanford

P. Caimi

16 Cancer Center, Cleveland Clinic/Case Comprehensive Cancer Center, Cleveland, United States of America

R.-O. Casasnovas

17 Department of Hematology, University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, France

T. Feldman

18 John Theurer Cancer Center, Hackensack Meridian Health, Hackensack

B. Hess

19 Division of Hematology and Medical Oncology, Department of Medicine, Medical University of South Carolina, Charleston, United States of America

M. Bastos-Oreiro

20 Haematology Department, Gregorio Marañón Health Research Institute, Hospital General Universitario Gregorio Marañón, Madrid, Spain

S. Iyengar

21 Royal Marsden Hospital, London, United Kingdom

S. Eisen

22 ADC Therapeutics SA, Epalinges, Switzerland

Y. Negievich

22 ADC Therapeutics SA, Epalinges, Switzerland

L. Wang

23 ADC Therapeutics America, Inc, Murray Hill

J. Wuerthner

22 ADC Therapeutics SA, Epalinges, Switzerland

A. F. Herrera

24 Department of Hematology & Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, United States of America